Literature DB >> 30190889

New insights in melanoma biomarkers: long-noncoding RNAs.

Ricardo Moreno-Traspas1,1, Igor Vujic1,2,1,2, Martina Sanlorenzo1,3,1,3, Susana Ortiz-Urda1,1.   

Abstract

Melanoma is one of the leading cancers worldwide, distinguished for its malignancy and low survival rates. Although the poor outcome could improve with an early diagnosis and a good monitoring of the disease, current melanoma biomarkers display several limitations which make them useless. Interestingly, long-noncoding RNAs are secreted into the bloodstream inside exosomes by a wide range of malignant cells, and several of them have been validated as promising circulating molecular signatures of other tumors, but not melanoma. In this review we propose to explore the booming field of long-noncoding RNAs in order to find potential candidates to be tested as novel melanoma biomarkers, with the ultimate goal of improving melanoma detection, diagnosis and prognosis.

Entities:  

Keywords:  biomarkers; cancer; lncRNAs; melanoma

Year:  2016        PMID: 30190889      PMCID: PMC6094599          DOI: 10.2217/mmt-2016-0008

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  86 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.

Authors:  S Ugurel; G Rappl; W Tilgen; U Reinhold
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma.

Authors:  R Garg; T A McPherson; B Lentle; F Jackson
Journal:  Can Med Assoc J       Date:  1979-05-05       Impact factor: 8.262

4.  S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.

Authors:  G Krähn; P Kaskel; S Sander; P J Waizenhöfer; S Wortmann; U Leiter; R U Peter
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

5.  S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.

Authors:  M Deichmann; A Benner; M Bock; A Jäckel; K Uhl; V Waldmann; H Näher
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

6.  Patterns of visceral metastasis in cutaneous melanoma: a descriptive study.

Authors:  J Marcoval; J R Ferreres; C Martín; S Gómez; R M Penín; M Ochoa de Olza; Á Fabra
Journal:  Actas Dermosifiliogr       Date:  2013-07-19

Review 7.  MAPK pathway inhibition in melanoma: resistance three ways.

Authors:  Claudia Wellbrock
Journal:  Biochem Soc Trans       Date:  2014-08       Impact factor: 5.407

8.  Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma.

Authors:  Yongjing Tian; Xiuying Zhang; Yinghua Hao; Zhengyu Fang; Yanling He
Journal:  Melanoma Res       Date:  2014-08       Impact factor: 3.599

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Authors:  Elin S Gray; Helen Rizos; Anna L Reid; Suzanah C Boyd; Michelle R Pereira; Johnny Lo; Varsha Tembe; James Freeman; Jenny H J Lee; Richard A Scolyer; Kelvin Siew; Chris Lomma; Adam Cooper; Muhammad A Khattak; Tarek M Meniawy; Georgina V Long; Matteo S Carlino; Michael Millward; Melanie Ziman
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.